Imperfect Information: Since Tumor Promotion By Prasugrel Was Unprovable, FDA Asked If It Was Biologically Plausible
This article was originally published in Pharmaceutical Approvals Monthly
In a setting of imperfect information regarding the hot-button issue of whether prasugrel has a tumor promotion effect, FDA put greater weight on the explanatory powers of modes of assessment that are normally overshadowed by clinical evaluation.
You may also be interested in...
In FDA’s review of Lilly/Daiichi Sankyo’s antiplatelet agent Effient (prasugrel) – a drug with broad potential use – it is notable that the approval was delayed not by unusual clinical questions, but rather by the agency’s efforts to be exceedingly thorough and scrupulous in the review.
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.